BIOVENTIX ORD 5P overview

Bioventix Plc - Holding(s) in Company PR Newswire London, December 29 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B4QVDF07 Issuer Name BIOVENTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Liontrust Investment Partners LLP City of registered office (if applicable) Country of registered office (if applicable) GB 4. Details of the shareholder...

Bioventix Plc - Result of AGM PR Newswire London, December 8 Bioventix plc (“Bioventix” or the “Company”) Result of AGM Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held earlier today, all resolutions put to shareholders were duly passed. For further information please contact: Bioventix plc Peter Harrison Bruce Hiscock Chief Executive Officer Chief Financial Officer Tel: 01252 728 001 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane Corporate Finance ECM Tel: 020...

Bioventix Plc - Director Dealing PR Newswire London, November 22 Bioventix plc (“Bioventix” or “the Company”) Director Dealing Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 22 November 2022 that on 21 November 2022 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 50 ordinary shares of 5 pence each...

Bioventix Plc - Posting of Annual Report and Notice of AGM PR Newswire London, November 8 8 November 2022 Bioventix plc ("Bioventix” or the "Company") Posting of Annual Report and Notice of AGM Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has today posted its Annual Report for the year ended 30 June 2022 together with a Notice of Annual General...

Bioventix Plc - Director Dealing PR Newswire London, October 26 Bioventix plc (“Bioventix” or “the Company”) Director Dealing Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has been notified that Bruce Hiscock , Chief Financial Officer of the Company, completed the following dealings in the Company’s ordinary shares of 5 pence in the Company...

Bioventix Plc - Results for the year ended 30 June 2022 PR Newswire London, October 24 Bioventix plc (“Bioventix” or “the Company”) Results for the year ended 30 June 2022 Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2022 . Highlights: · Revenue up 7% to £11.72 million (2021: £10.93 million) · Profit...

Bioventix Plc - Trading Update & Notice of Results PR Newswire London, September 13 Bioventix plc (“Bioventix” or “the Company”) Trading Update & Notice of Results Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, is pleased to announce a trading update for the year ended 30 June 2022 (“FY2022”). As announced in our interim results to 31 December 2021 , we had a...

Bioventix Plc - Holding(s) in Company PR Newswire London, August 25 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B4QVDF07 Issuer Name BIOVENTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Danske Bank A/S City of registered office (if applicable) Copenhagen Country of registered office (if applicable) Denmark 4. Details of the shareholder Name...